Page 42
FEATURE | Biosciences
Trinity and Biosciences
Advances in biomedical scientific research lead to major improvements in human health and welfare and are significant economic drivers.
Trinity’s strength in biomedical sciences is one of the main forces behind its international standing. To copper-fasten Trinity’s position as a leading international scientific university, it has started the construction of an ambitious 35,000 sq. m. Biosciences Development due to open in early 2011.
The objective is to consolidate pre-clinical bioscience research activities across five schools – Chemistry; Engineering; Biochemistry & Immunology; Medicine; Pharmacy & Pharmaceutical Sciences.
The programme of research for this facility builds on Trinity’s recognised expertise in immunology and its integrating role in diseases such as cancer and field of medical device technologies. Three interlinked centres of research will be created: CSI-Dublin: Centre for Study of Immunology; C2D2: Centre for Cancer Drug Discovery; CMDT: Centre for Medical Device Technologies. With the new Development, the scientists will collaborate in a multidisciplinary environment to challenge convention and push the boundaries of discovery in the best tradition of Trinity College Dublin. The building will accommodate around 1,000 researchers by 2013.
Coinciding with the tercentenary of the School of Medicine in 2011, the development will house all pre-clinical medical education and training activities. In a departure for an academic institution, researchers will work alongside industry in industry-academic collaborative and commercial lab space.
Trinity’s strategy for building research excellence is anchored around its people. Our researchers are motivated by a desire to understand disease processes and to interrogate these processes in a way that can translate to a health/societal benefit. TCD bioscience researchers have delivered the technologies that underpinned the nicotine patch, they’ve identified new genes for major diseases such as childhood eczema, they’ve discovered why some people are more prone to malaria or lung cancer, and they’ve pushed the boundaries of our understanding of how diseases work – Alzheimer’s, cancer, arthritis. Our international rankings show our outputs are amongst the best in the world. The opportunity now is to translate this quality to wider societal and economic benefit.
(Diagram entitled: BioEngineering Medicine Chemistry Biochemistry & Immunology Pharmacy & Pharmaceutical Sciences)
Building Progress
• Planning permission granted.
• Tender for the construction completed: PJ Walls selected.
• Builders came on site in May 2008.
• Estimated building cost is €131m.
• TCD secured loan approval of €75m from the European Investment Bank to start construction.
• A major campaign is under way to raise public and private funds for the building.
For more information please visit
www.tcd.ie/biosciences/
If you are able to help making the Biosciences Development a reality please contact Dr David Lloyd, Dean of Research, at
biosciences@tcd.ie or
dean.of.research@tcd.ie
(Photo captioned: Entrance from Pearse Street (architects’ rendering))
40 | Trinity Today
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84